Follow
XSpray Pharma AB
Nasdaq First North Sweden (Sweden)
XSpray Pharma AB is a product development company with several product candidates in clinical development. It develops, sells and licenses generic versions of marketed cancer drugs, protein kinase inhibitors. The company primarily develops protein kinase inhibitors (PKI) for targeted cancer treatment.
Sector:
HEALTH CARE
>
Biotechnology
Sector:
TECHNOLOGY
Instruments & Events
The shares and options available for this company. Including past events like IPOs, direct listings and exercise periods.
Type
Ticker
ISIN
Market
SHARE
XSPRAY
SE0009973563
Nasdaq First North Sweden
Sweden (SE)
Details of share in XSpray Pharma AB with ticker XSPRAY
Status
Active
Order book id
Amount of instruments
16 751 622
Par value
1.2000
Market cap
Currency
SEK
Segment
First North
First trading date
28 Sep 2017
Terms
Type
Price
Pre-money valuation
Time
Files
IPO
22.00 SEK
139.8M SEK
28 Aug - 11 Sep 2017
IPO in XSpray Pharma AB
Market
Nasdaq First North Sweden
Subscription period
28 Aug - 11 Sep 2017
Subscription price
Price per share
22.00 SEK
Target to raise
132 000 000 SEK
Types
Pre-money valuation
139 800 000 SEK
Subscription block size
Minimum subscription
250
Record date
Offer status
Closed
Listing status
Listed
First trading date
28 Sep 2017
Issue terms
Addresses the public in Sweden and institutional investors.
Type
Price
Pre-money valuation
Time
Files
New issue
65.00 SEK
803M SEK
20 Feb - 20 Feb 2018
-
Share issue in XSpray Pharma AB
Market
Nasdaq First North Sweden
Subscription period
20 Feb - 20 Feb 2018
Subscription price
Price per share
65.00 SEK
Target to raise
88 000 000 SEK
Types
Share issue
Pre-money valuation
803 000 000 SEK
Subscription block size
Minimum subscription
Record date
Offer status
Closed
Listing status
Listed
Issue terms
The new share issue is aimed at a number of selected investors who will subscribe to it in full in accordance with separate agreements including Robur Ny Teknik, the Niclas Ericsson family, the Union and Nyenburgh.
Type
Price
Pre-money valuation
Time
Files
New issue
67.00 SEK
918.3M SEK
06 Dec - 06 Dec 2018
-
Share issue in XSpray Pharma AB
Market
Nasdaq First North Sweden
Subscription period
06 Dec - 06 Dec 2018
Subscription price
67.00 SEK
Price per share
67.00 SEK
Target to raise
92 000 000 SEK
Types
Share issue
Pre-money valuation
918 300 000 SEK
Subscription block size
Minimum subscription
Record date
Offer status
Closed
Listing status
Listed
Issue terms
Directed issue, through an accelerated bookbuilding procedure. Signed by a number of Swedish and international institutional investors, including the Union, the Third AP Fund and the Fourth AP Fund.
Type
Price
Pre-money valuation
Time
Files
New issue
73.00 SEK
1.1B SEK
05 Dec - 06 Dec 2019
-
Share issue in XSpray Pharma AB
Market
Nasdaq First North Sweden
Subscription period
05 Dec - 06 Dec 2019
Subscription price
Price per share
73.00 SEK
Target to raise
122 300 000 SEK
Types
Share issue
Pre-money valuation
1 100 600 000 SEK
Subscription block size
Minimum subscription
Record date
Offer status
Closed
Listing status
Listed
Issue terms
Directed issue through an accelerated bookbuilding process handled by Carnegie Investment Bank and Zonda Partners.
Comments for offer & related information
Amount of shares in issue 1 675 162. In conjunction with the Issue, the Company has engaged Carnegie Investment Bank and Zonda Partners as Joint Bookrunners and Vinge as legal adviser to the Company. A group of Swedish and international institutional investors, among others C WorldWide Asset Management, Fourth Swedish National Pension Fund, Swedbank Robur, TIN Fonder, Third Swedish National Pension Fund and Unionen have subscribed for shares in the Issue.
The Issue is intended to be carried out through an accelerated building process (the “Bookbuilding”) which will commence immediately. Pricing and allocation of the new shares are expected to take place before the beginning of trading on Nasdaq First North Growth Market at 09:00 CET on 6 December 2019.
Type
Price
Pre-money valuation
Time
Files
Market move
27 Mar 2020
Listing of XSpray Pharma AB on NASDAQ STOCKHOLM
Move from
Nasdaq First North Sweden
Move to
NASDAQ STOCKHOLM
Status
Listed
Comments for listing & related information
Documents
People
Number of Employees
17 people
Per Erik Andersson
CEO
Michael Wolff Jensen
Chairman of the board
Michael Wolff Jensen
Board member
Carl-Johan Spak
Board member
Hans Arwidsson
Board member
Maris Hartmanis
Board member
Torbjörn Koivisto
Board member
Company Details
Sector
HEALTH CARE, TECHNOLOGY

Address
Råsundavägen 12
Zip code
169 67
City/district
Solna
Country
Sweden (SE)
Registration number
556649-3671
LEI code
549300NGRQCNZ3X4L157
First trade date
28 Sep 2017
Registration date
09 Oct 2003
Short name
XSpray Pharma

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More

Create Your FREE Account to stay Up To Date